skip to Main Content

Cell-Based Pro-Drug Strategy for Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
PharmaCyte Biotech, which specializes in cell-based treatments for cancer and diabetes has announced that its clinical trial product, CypCaps™, remains stable and active after 18 months when stored at -80°C. The next timepoint milestone for the product comes at 24 months. CypCaps are genetically engineered human cells, specifically engineered to treat unresectable pancreatic cancer, and encapsulated using PharmaCyte’s Cell-in-a-Box® technology.

Cell-in-a-Box is a multi-step process. Cells are first suspended in a medium containing a proprietary polymer plus sodium cellulose sulfate. Droplets created from this suspension fall into a solution containing another polymer. The two polymers self-assemble into a membrane that surrounds each 700–800mm-sized droplet and its cargo of approximately 20,000 living cells. The number of cells delivered varies according to the size of the cell. Read more . . . 


Back To Top